| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Patient-specific induced pluripotent stem-cell models for long-QT syndrome.
|
N Engl J Med
|
2010
|
9.19
|
|
2
|
Multipotent embryonic isl1+ progenitor cells lead to cardiac, smooth muscle, and endothelial cell diversification.
|
Cell
|
2006
|
7.21
|
|
3
|
Inactivating mutations in NPC1L1 and protection from coronary heart disease.
|
N Engl J Med
|
2014
|
4.94
|
|
4
|
The renewal and differentiation of Isl1+ cardiovascular progenitors are controlled by a Wnt/beta-catenin pathway.
|
Cell Stem Cell
|
2007
|
3.54
|
|
5
|
Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial.
|
Lancet
|
2012
|
3.12
|
|
6
|
Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention.
|
Circulation
|
2012
|
2.32
|
|
7
|
Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial.
|
Lancet
|
2011
|
2.10
|
|
8
|
Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia.
|
EMBO Mol Med
|
2012
|
1.93
|
|
9
|
Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study.
|
J Am Coll Cardiol
|
2010
|
1.93
|
|
10
|
Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial.
|
Eur Heart J
|
2009
|
1.81
|
|
11
|
Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.
|
J Am Coll Cardiol
|
2009
|
1.73
|
|
12
|
Prognostic value of sensitive troponin T in patients with stable and unstable angina and undetectable conventional troponin.
|
Am Heart J
|
2011
|
1.70
|
|
13
|
ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention.
|
Eur Heart J
|
2010
|
1.56
|
|
14
|
One-year outcomes with abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary interventions in patients with non-ST-segment elevation myocardial infarction: updated results from the ISAR-REACT 4 trial.
|
EuroIntervention
|
2013
|
1.47
|
|
15
|
Bare metal vs. drug-eluting stents for extracranial vertebral artery disease: a meta-analysis of nonrandomized comparative studies.
|
J Endovasc Ther
|
2014
|
1.43
|
|
16
|
Mouse and human induced pluripotent stem cells as a source for multipotent Isl1+ cardiovascular progenitors.
|
FASEB J
|
2009
|
1.43
|
|
17
|
Gene transfer of the pancaspase inhibitor P35 reduces myocardial infarct size and improves cardiac function.
|
J Mol Med (Berl)
|
2005
|
1.42
|
|
18
|
Randomised, double-blind trial on the value of tapered discontinuation of clopidogrel maintenance therapy after drug-eluting stent implantation. Intracoronary Stenting and Antithrombotic Regimen: CAUTION in Discontinuing Clopidogrel Therapy--ISAR-CAUTION.
|
Thromb Haemost
|
2014
|
1.42
|
|
19
|
Incidence and prognostic value of bleeding after percutaneous coronary intervention in patients older than 75 years of age.
|
Catheter Cardiovasc Interv
|
2013
|
1.40
|
|
20
|
Correlates of poor outcome among patients with bleeding after coronary interventions.
|
Coron Artery Dis
|
2014
|
1.39
|
|
21
|
2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents.
|
J Am Coll Cardiol
|
2010
|
1.38
|
|
22
|
Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome.
|
EMBO J
|
2013
|
1.24
|
|
23
|
Essential myosin light chain as a target for caspase-3 in failing myocardium.
|
Proc Natl Acad Sci U S A
|
2002
|
1.21
|
|
24
|
Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction.
|
N Engl J Med
|
2011
|
1.20
|
|
25
|
Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography.
|
Heart
|
2013
|
1.19
|
|
26
|
Rationale and design of a randomised clinical trial comparing vascular closure device and manual compression to achieve haemostasis after diagnostic coronary angiography: the Instrumental Sealing of ARterial puncture site - CLOSURE device versus manual compression (ISAR-CLOSURE) trial.
|
EuroIntervention
|
2014
|
1.16
|
|
27
|
Morphological assessment of renal arteries after radiofrequency catheter-based sympathetic denervation in a porcine model.
|
J Hypertens
|
2012
|
1.12
|
|
28
|
Prognostic value of bleeding after percutaneous coronary intervention in patients with diabetes.
|
EuroIntervention
|
2014
|
1.10
|
|
29
|
Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial.
|
J Am Coll Cardiol
|
2011
|
1.07
|
|
30
|
Five-year clinical outcomes of sirolimus-eluting versus paclitaxel-eluting stents in high-risk patients.
|
Catheter Cardiovasc Interv
|
2011
|
1.07
|
|
31
|
Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial.
|
Circ Cardiovasc Interv
|
2010
|
1.04
|
|
32
|
Modulation of hERG potassium channel gating normalizes action potential duration prolonged by dysfunctional KCNQ1 potassium channel.
|
Proc Natl Acad Sci U S A
|
2012
|
1.03
|
|
33
|
Induced pluripotent stem cell-derived cardiomyocytes: a versatile tool for arrhythmia research.
|
Circ Res
|
2013
|
1.03
|
|
34
|
Embryonic heart progenitors and cardiogenesis.
|
Cold Spring Harb Perspect Med
|
2013
|
1.01
|
|
35
|
Pluripotent stem cell models of human heart disease.
|
Cold Spring Harb Perspect Med
|
2013
|
1.01
|
|
36
|
Prognostic value of access and non-access sites bleeding after percutaneous coronary intervention.
|
Circ Cardiovasc Interv
|
2013
|
0.96
|
|
37
|
Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting versus Zotarolimus-eluting Stents (ISAR-TEST 5) trial.
|
Circulation
|
2011
|
0.95
|
|
38
|
Development. ES cells to the rescue.
|
Science
|
2004
|
0.95
|
|
39
|
Zotarolimus- versus everolimus-eluting stents for unprotected left main coronary artery disease.
|
J Am Coll Cardiol
|
2013
|
0.89
|
|
40
|
Multipotent progenitor cells in regenerative cardiovascular medicine.
|
Pediatr Cardiol
|
2009
|
0.87
|
|
41
|
Live fluorescent RNA-based detection of pluripotency gene expression in embryonic and induced pluripotent stem cells of different species.
|
Stem Cells
|
2015
|
0.87
|
|
42
|
Impaired platelet function reduces myocardial infarct size in Galphaq knock-out mice in vivo.
|
J Mol Cell Cardiol
|
2007
|
0.86
|
|
43
|
Everolimus-eluting versus sirolimus-eluting stents: a meta-analysis of randomized trials.
|
Circ Cardiovasc Interv
|
2011
|
0.85
|
|
44
|
A potential life-threatening complication after implantation of a bioresorbable scaffold for coronary stenting within a mechanically stressed region.
|
Clin Res Cardiol
|
2015
|
0.84
|
|
45
|
Very late stent thrombosis 42 months after implantation of sirolimus-eluting stent and discontinuation of antiplatelet therapy.
|
Case Rep Med
|
2009
|
0.84
|
|
46
|
Direct nkx2-5 transcriptional repression of isl1 controls cardiomyocyte subtype identity.
|
Stem Cells
|
2015
|
0.84
|
|
47
|
Incidence and impact on prognosis of bleeding during percutaneous coronary interventions in patients with chronic kidney disease.
|
Clin Res Cardiol
|
2013
|
0.83
|
|
48
|
Simultaneous positron emission tomography/magnetic resonance imaging identifies sustained regional abnormalities in cardiac metabolism and function in stress-induced transient midventricular ballooning syndrome: a variant of Takotsubo cardiomyopathy.
|
Circulation
|
2012
|
0.83
|
|
49
|
Bivalirudin versus heparin in patients treated with percutaneous coronary intervention: a meta-analysis of randomised trials.
|
EuroIntervention
|
2015
|
0.83
|
|
50
|
Comparison of prasugrel and bivalirudin vs clopidogrel and heparin in patients with ST-segment elevation myocardial infarction: Design and rationale of the Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 trial.
|
Clin Cardiol
|
2014
|
0.83
|
|
51
|
Modeling long-QT syndromes with iPS cells.
|
J Cardiovasc Transl Res
|
2012
|
0.82
|
|
52
|
Selective attenuation of norepinephrine release and stress-induced heart rate increase by partial adenosine A1 agonism.
|
PLoS One
|
2011
|
0.82
|
|
53
|
Randomized comparison of ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy--design and rationale of the iNtracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 trial.
|
J Cardiovasc Transl Res
|
2013
|
0.82
|
|
54
|
Induced pluripotent stem cells in cardiovascular research.
|
Rev Physiol Biochem Pharmacol
|
2012
|
0.81
|
|
55
|
Endovascular therapy for steno-occlusive subclavian and innominate artery disease.
|
Circ J
|
2015
|
0.80
|
|
56
|
Five-year outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease: final results from the ISAR-TEST 4 randomised trial.
|
EuroIntervention
|
2016
|
0.79
|
|
57
|
Radial artery applanation tonometry for continuous noninvasive arterial blood pressure monitoring in the cardiac intensive care unit.
|
Clin Res Cardiol
|
2015
|
0.79
|
|
58
|
Liver laceration associated with the use of a chest compression device.
|
Resuscitation
|
2009
|
0.78
|
|
59
|
Safety and efficacy of a potential treatment algorithm by using manual compression repair and ultrasound-guided thrombin injection for the management of iatrogenic femoral artery pseudoaneurysm in a large patient cohort.
|
Circ Cardiovasc Interv
|
2014
|
0.78
|
|
60
|
Predictors of antiplatelet response to prasugrel during maintenance treatment.
|
Platelets
|
2014
|
0.78
|
|
61
|
Bleeding after percutaneous coronary intervention with Bivalirudin or unfractionated Heparin and one-year mortality.
|
Am J Cardiol
|
2009
|
0.78
|
|
62
|
Quantitative analysis of apoptotic markers in human end-stage heart failure.
|
Eur J Heart Fail
|
2008
|
0.78
|
|
63
|
Microvascular obstruction in patients with non-ST-elevation myocardial infarction: a contrast-enhanced cardiac magnetic resonance study.
|
Int J Cardiovasc Imaging
|
2014
|
0.77
|
|
64
|
Recapitulating long-QT syndrome using induced pluripotent stem cell technology.
|
Pediatr Cardiol
|
2012
|
0.77
|
|
65
|
Mutational analysis of the human MESP1 gene in patients with congenital heart disease reveals a highly variable sequence in exon 1.
|
Eur J Med Genet
|
2013
|
0.77
|
|
66
|
Massive thrombus burden with recurrence of intracoronary thrombosis early after stenting and delayed onset of prasugrel action in a patient with ST-elevation myocardial infarction and cardiac shock.
|
Thromb Haemost
|
2011
|
0.77
|
|
67
|
Retroviral infection and selection of culture-derived platelets allows study of the effect of transgenes on platelet physiology ex vivo and on thrombus formation in vivo.
|
Arterioscler Thromb Vasc Biol
|
2005
|
0.77
|
|
68
|
Association of increased CD8+ and persisting C-reactive protein levels with restenosis in HIV patients after coronary stenting.
|
AIDS
|
2016
|
0.76
|
|
69
|
Negating the dominant-negative allele: a new treatment paradigm for arrhythmias explored in human induced pluripotent stem cell-derived cardiomyocytes.
|
Eur Heart J
|
2013
|
0.75
|
|
70
|
Reply: Aspirin Treatment and Outcomes After Percutaneous Coronary Intervention: Results of the ISAR-ASPI Registry.
|
J Am Coll Cardiol
|
2015
|
0.75
|
|
71
|
Subtype-specific promoter-driven action potential imaging for precise disease modelling and drug testing in hiPSC-derived cardiomyocytes.
|
Eur Heart J
|
2017
|
0.75
|
|
72
|
MicroRNAs in a cardiac loop: progenitor or myocyte?
|
Dev Cell
|
2010
|
0.75
|
|
73
|
Reply: Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation.
|
J Am Coll Cardiol
|
2015
|
0.75
|
|
74
|
Reply: Duration of Triple Therapy: A Clinical Question Yet to Be Answered.
|
J Am Coll Cardiol
|
2015
|
0.75
|
|
75
|
Safety and efficacy of different stent types for the endovascular therapy of extracranial vertebral artery disease.
|
Clin Res Cardiol
|
2013
|
0.75
|
|
76
|
Angiographic and clinical outcomes of patients treated with drug-coated balloon angioplasty for in-stent restenosis after coronary bifurcation stenting with a two-stent technique.
|
EuroIntervention
|
2016
|
0.75
|
|
77
|
Changes in high-sensitivity troponin after drug-coated balloon angioplasty for drug-eluting stent restenosis.
|
EuroIntervention
|
2017
|
0.75
|
|
78
|
Unusual use of a standard percutaneous transluminal coronary angioplasty balloon catheter to the rescue.
|
Eur Heart J
|
2008
|
0.75
|
|
79
|
Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stents.
|
Thromb Haemost
|
2017
|
0.75
|
|
80
|
Renal failure after renal sympathetic ablation in a patient with chronic kidney disease--which came first, the chicken or the egg?
|
Int J Cardiol
|
2013
|
0.75
|
|
81
|
Stem cell mobilisation by granulocyte-colony stimulating factor in patients with acute myocardial infarction. Long-term results of the REVIVAL-2 trial.
|
Thromb Haemost
|
2016
|
0.75
|
|
82
|
How should I treat a complex left subclavian artery stenosis involving the vertebral artery in a patient with subclavian steal syndrome and left internal mammary artery bypass graft?
|
EuroIntervention
|
2015
|
0.75
|
|
83
|
Genetic risk of restenosis after percutaneous coronary interventions in the era of drug-eluting stents.
|
Coron Artery Dis
|
2014
|
0.75
|
|
84
|
Impact of stent size on angiographic and clinical outcomes after implantation of everolimus-eluting bioresorbable scaffolds in daily practice: insights from the ISAR-ABSORB registry.
|
EuroIntervention
|
2016
|
0.75
|
|
85
|
Drug-eluting stents versus bare-metal stents for the prevention of restenosis in patients with renovascular disease.
|
EuroIntervention
|
2017
|
0.75
|
|
86
|
Immature platelets as a novel biomarker for adverse cardiovascular events in patients after non-cardiac surgery.
|
Thromb Haemost
|
2017
|
0.75
|
|
87
|
Endothelial RAGE exacerbates acute postischaemic cardiac inflammation.
|
Thromb Haemost
|
2016
|
0.75
|
|
88
|
Outcomes of patients treated with durable-polymer platinum-chromium everolimus-eluting stents: a meta-analysis of randomized trials.
|
EuroIntervention
|
2017
|
0.75
|
|
89
|
Impact of bivalirudin on post-procedural epicardial blood flow, risk of stent thrombosis and mortality after percutaneous coronary intervention.
|
EuroIntervention
|
2016
|
0.75
|
|
90
|
Time does not heal all wounds: very late stent thrombosis eight years after implantation of a sirolimus-eluting stent due to positive remodelling, saccular evaginations and marked vascular inflammation.
|
EuroIntervention
|
2013
|
0.75
|
|
91
|
Drug-coated balloon angioplasty for in-stent restenosis of femoropopliteal arteries. A meta-analysis.
|
EuroIntervention
|
2017
|
0.75
|
|
92
|
Transcatheter aortic-valve endocarditis confirmed by transesophageal echocardiography.
|
Circulation
|
2013
|
0.75
|
|
93
|
Bleeding after percutaneous coronary intervention in women and men matched for age, body mass index, and type of antithrombotic therapy.
|
Am Heart J
|
2013
|
0.75
|